Spectrum of Biliary and Nonbiliary Neoplasms Growing and Spreading Within the Lumen of the Bile Ducts. [PDF]
Nakanuma Y, Sato Y, Kakuda Y, Oishi T.
europepmc +1 more source
ABSTRACT Background Cell therapy, particularly those utilizing mesenchymal stem/stromal cells (MSCs), is gaining traction as a therapeutic option for regenerative treatment in patients with limited therapeutic options. Although the safety of MSC‐based interventions is well established, uncertainties remain regarding how genetic abnormalities and ...
Marzena Zychowicz +12 more
wiley +1 more source
Is cancer the result of uncontrolled cellular growth? a glance into the tumorigenic process. [PDF]
Castro-Oropeza R +5 more
europepmc +1 more source
A Spotlight on Yolk‐sac Tumors: Molecular Pathology, Current Diagnostics, and Novel Therapeutics
ABSTRACT Background Yolk‐sac tumors are an aggressive subtype of testicular cancer that significantly contribute to disease progression and therapy resistance, especially in adults. While testicular cancer generally has high cure rates with cisplatin‐based treatment, adult yolk‐sac tumors often appear as components of mixed tumors with poor response to
Evangelos Prokakis +3 more
wiley +1 more source
Checkpoint blockade and the stem-like T cell trade-off. [PDF]
Mazet JM, Joyce JA.
europepmc +1 more source
Clinical scenario Canine osteoarthritis (OA) is a degenerative joint disease and is one of the most common chronic conditions in dogs and other species. The management of OA remains a longstanding focus in veterinary medicine. Traditionally, nonsteroidal anti‐inflammatory drugs (NSAIDs) have been the first‐line treatment option for canine OA. Recently,
X Yang, P Macarthur
wiley +1 more source
Integrated single-cell and bulk transcriptomic analyses reveal a stem-like epithelial subpopulation in adenocarcinoma of the esophagogastric junction and identify VASN as a novel regulator of tumor stemness. [PDF]
Zheng H, Wang S, Liu H, Wang J, Hu B.
europepmc +1 more source
Summary This UK‐based retrospective analysis describes real‐world treatment patterns and outcomes in 175 patients with accelerated (AP, n = 69) or blast‐phase (BP, n = 106) ‘Philadelphia‐negative’ myeloproliferative neoplasms (MPN‐AP/BP) diagnosed between 2013 and 2025. Median age at transformation was 71 years.
Alexandros Rampotas +35 more
wiley +1 more source
The Hippo signaling pathway in pediatric brain tumors: molecular mechanisms and therapeutic opportunities. [PDF]
Papanikolaou MA +3 more
europepmc +1 more source
RHEBL1 expression is activated by the Oct4-Sox2 complex in oral squamous cell carcinoma. [PDF]
Qiu F +8 more
europepmc +1 more source

